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A large variety of human tumours manifest a heterozygous or
homozygous deletion in the 9p21 chromosome region. The list
includes malignant melanoma, glioma, lung, bladder, pancreatic
and renal cancers (Kamb et al, 1994; Nobori et al, 1994), as well as
gynaecological tumours (reviewed by Wong et al, 1997). Two
putative tumour suppressor genes have been identified in this
region: p16 (also known as p16INK4A, cyclin-dependent kinase
4 inhibitor, CDK4I, CDKN2, and MTS1), and p15 (p15INK4B).
The p16 gene makes two different proteins, p16 and p19ARF (p19
alternative reading frame), using different overlapping reading
frames, starting with different first exons. The p16 protein uses
exon 1a, and p19ARF uses exon 1b; these two exons are alterna-
tively spliced to the same second and third exons. The p16 and p15
proteins belong to a family of negative regulators of the cell cycle.
Specific binding of p16 protein to the CDK4 or CDK6 cyclin-
dependent protein kinases inhibits the phosphorylation activity of
CDK–cyclin D complexes towards the nuclear RB/E2F protein
complex (Serrano et al, 1993). p16 normally prevents phosphoryl-
ation of RB, resulting in RB’s retention of E2F. Failure to release
E2F at the late G1 checkpoint blocks the cell from entering the S
phase (Hengstschläger et al, 1996; Lukas et al, 1996). The p19ARF
protein, although it has an unrelated amino acid sequence, has cell
cycle arresting functions. It is the p16 protein that now appears to
be the major target of mutations and deletions at the 9p21 loci.
The p15 (MTS2) putative tumour suppressor gene is located
25 kb centromeric of the p16 gene on 9p. p15 contains sequences
highly homologous to exon 2 of p16 and, like p16, inhibits both
CDK4 and CDK6 kinase activities (Guan et al, 1994; Hannon and
Beach, 1994). Homozygous deletions of p15 and hypermethyla-
tion-associated loss of p15 expression have been reported in
glioblastomas (Jen et al, 1994).
The p16/p19ARF and p15 genes appear to play variably important
roles in human tumorigenesis, with critical tissue specificities and
uncertain implications for clinical prognoses. Little is currently
known about the potential role of these genes in reproductive tract
biology, and specifically in uterine tumours. We have begun to
examine the expression of the p16 gene at the level of mRNA and
protein, the methylation status of the 5¢-CpG island of p16 exon
1a, and for p16 point mutations and homozygous deletions in
these tumours. We have also analysed the p15 gene for mutations
and homozygous deletions. We report that the inactivation of the
p16 gene, either by homozygous gene deletion, mutation or loss of
protein expression, occurs in a small but significant subset of these
uterine tumours.
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Summary The roles of the p16 and p15 inhibitor of cyclin-dependent kinase tumour suppressor genes were examined in human uterine
cervical and endometrial cancers. p16 mRNA, examined by reverse transcription polymerase chain reaction (RT-PCR), was significantly
reduced in five of 19 (26%) cervical and four of 25 (16%) endometrial tumours. Reduced expression of p16 protein, detected by
immunohistochemistry, occurred even more frequently, in nine of 33 (27%) cervical and seven of 37 (19%) endometrial tumours.
Hypermethylation of a site within the 5¢-CpG island of the p16 gene was detected in only one of 32 (3%) cervical tumours and none of 26
endometrial tumours. Homozygous p16 gene deletion, evaluated by differential PCR analysis, was found in four of 40 (10%) cervical tumours
and one of 38 (3%) endometrial tumours. Homozygous deletion of p15 was found in three of 40 (8%) cervical tumours and one of 38 (3%)
endometrial tumours. PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of
78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). Three were mis-sense mutations, one in
codon 74 (CTG®ATG) and one in codon 129 (ACC®ATC), both in cervical carcinomas, and the other was in codon 127 (GGG®GAG) in an
endometrial carcinoma. There was one non-sense mutation, in codon 50 (CGA®TGA), in an endometrial carcinoma. The remaining two were
silent somatic cell mutations, both in cervical carcinomas, resulting in no amino acid change. These observations suggest that inactivation of
the p16 gene, either by homologous deletion, mutation or loss of expression, occurs in a subset of uterine tumours.
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MATERIALS AND METHODS
Tissue samples
Samples used in this study were randomly obtained from patients
who had been admitted to the Department of Obstetrics and
Gynecology at the Osaka University Hospital in Osaka, Japan.
Informed consent was obtained from all patients. No initial
chemotherapy or radiation therapy was performed prior to tumour
sampling. Tissues were mostly obtained by hysterectomy, except
for those cases with advanced clinical stages in which surgery was
not performed as the primary treatment. Tissues were sampled for
histopathological diagnosis, and remainders were quick frozen
for later extraction of RNA and DNA. We evaluated a total of
19 cervical tumours (16 squamous cell carcinomas and three
adenocarcinomas) and a total of 25 endometrial tumours (22
endometrioid adenocarcinomas and three complex hyperplasia
with atypia) for p16 mRNA expression. RNA was extracted with
guanidinium isothiocyanate, followed by centrifugation in a
caesium chloride solution. RNA was also extracted from histo-
logically normal tissues (two ovaries, four cervixes and four
endometrium). High molecular weight DNA was extracted from
40 cervical tumours (35 squamous cell carcinomas and five
adenocarcinomas) and 38 endometrial tumours (30 endometrioid
adenocarcinomas and eight complex hyperplasias with atypia)
following the procedures previously described (Enomoto et al,
1991).
RT-PCR analysis
For cDNA synthesis, 1 mg of total cellular RNA was annealed with
random hexamers at 26°C for 10 min. The RNA was transcribed
with 10 units of AMV reverse transcriptase (Gibco-BRL,
Rockville, MD, USA) at 42°C for 90 min in the presence of the
ribonuclease inhibitor RNasin (1 ml; Promega, Madison, WI,
USA). A cDNA aliquot corresponding to 200–500 ng of RNA was
used as the template for polymerase chain reaction (PCR) amplifi-
cation. Primers used were 5¢-TTATTTGAGCTTTGGTTCTG-3¢
for the p16 antisense primer, which corresponds to nucleotides
894–913 in the cDNA sequence, and 5¢-CCCGCTTTCG-
TAGTTTTCAT-3¢ for the sense primer, which corresponds to
559–578 in the cDNA sequence. For control of reverse transcrip-
tion (RT)-PCR, a 319-bp fragment of b-actin cDNA was also
amplified using primers previously described (Fuqua et al, 1990).
The PCR reactions for all the following experiments were in a
25 ml volume. This particular PCR reaction mixture contained
cDNA (200–500 ng), 0.5 mM of each primer for p16, or 0.05 mM of
each primer for b-actin, and PCR buffer (100 mM of each deoxy-
nucleotide triphosphate, 1.5 mM magnesium chloride, 50 mM
potassium chloride, 10 mM Tris-HCl pH 8.3 and 0.01% gelatin).
All the PCR reactions in this manuscript were initially denatured
at 94°C for 5 min, then 0.5 U of Taq polymerase (Perkin-Elmer
Cetus, Norwalk, CT, USA) was added. One amplification cycle for
the p16 fragment consisted of 1 min each at 94°C, 58°C and 72°C.
One cycle for the b-actin fragment consisted of 1 min each at
94°C, 50°C and 72°C. A total of 28 cycles of PCR amplification
was performed. PCR products were fractionated in 2.5% agarose
gels, and visualized by staining with ethidium bromide. Band
quantitation was done by densitometric analysis.
Immunohistochemistry
The tissue localization of p16 protein was determined immuno-
histochemically by the labelled streptavidin–biotin method on
formalin-fixed paraffin-embedded tissues. Sections were placed
on glass slides coated with 0.02% poly-L-lysine. Deparaffinized
sections were immersed in 10 mM sodium citrate buffer (pH 6.0)
and autoclaved at 121°C for 15 min. The immuno-detection proce-
dures were carried out according to the manufacturer’s recommen-
dations. A polyclonal rabbit anti-human p16INK4 protein
antibody (1:100 dilution; PharMingen, San Diego, CA, USA) was
used as the primary antibody. Sections from normal ovary and
normal proliferative endometrium were used as positive controls.
Sections incubated with normal rabbit pre-immune serum, instead
of the corresponding primary rabbit antibody, were used as
negative controls. The relative number of immunoreactive cells
was scored from a negative reaction to a grade 2(+) staining for
p16, as follows: (–, no staining was observed in any tumour
cell;  ±, less than 50% of the tumour cells were stained positively;
+, more than 50% of the tumour cells were stained positively).
Analysis of the methylation status of the p16 gene
The methylation status of the p16 gene promoter region 5¢-CpG
island of which extends 3¢ into the first exon, was analysed using
multiplex PCR analysis, as described by Lo et al (1996). One mg
of high molecular weight DNA was digested with 10 U of the
methylation-sensitive restriction enzyme Sma I at 30°C for 12 h,
then another 10 U of Sma I was added and digestion was continued
for an additional 12 h. The digested DNA was then subjected to
multiplex PCR analysis. Primers used were the 2F and 1108R
primers described by Kamb et al (1994), which amplify exon 1 of
the p16 gene, including a methylation-status diagnostic Sma I site.
As an internal control, the sequence tagged site (STS) 1063.7 on
the distal side of the p16 gene was also co-amplified. The high
molecular weight DNA was alternatively digested with 10 U of the
methylation-sensitive enzyme Eag I at 37°C for 12 h, then another
10 U of Eag I was added and digestion was continued for an
additional 12 h. PCR amplification was performed as described
above. Undigested tumour DNA was amplified as an additional
control.
Detection of homozygous deletion of p16 gene by
differential PCR analysis
To detect homozygous deletion of the p16 gene, a 111-bp fragment
of exon 2–intron 2 was amplified by PCR. Primers used were
5¢-CAAATTCTCAGATCATCAGTCCT-3¢ for the p16 anti-
sense primer, which corresponds to nucleotide 502–524, and
5¢-GATGTCGCACGGTACCTG-3¢ for the sense primer, which
corresponds to nucleotide 414–431. For internal control of PCR,
we simultaneously amplified a 136-bp fragment in the promotor
region of the transferrin receptor gene. Primers used were
5¢-CAGGATGAAGGGAGGACAC-3¢ for the transferrin receptor
gene antisense primer, which corresponds to nucleotides 405–423,
and 5¢-GCTATAAACCGCCGGTTAG-3¢ for the sense primer,
which corresponds to nucleotides 288–306 (Owen and Kuëhn,
1987). The PCR reaction mixture contained genomic DNA
(0.1 mg), 0.1 mM of each primer for p16, 0.1 mM of each primer for
the transferrin receptor gene and PCR buffer. One cycle of PCR
consisted of 30 s each at 94°C and 60°C. A total of 25 cycles
of PCR was performed. The PCR products were separated by
electrophoresis on a 12% polyacrylamide gel and the bands were
visualized by ethidium bromide staining under UV light and
photographed.460 R Nakashima et al
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Detection of p16 and p15 gene mutation by PCR-SSCP
analysis
Exons 1–3 of the p16 gene and exon 2 of the p15 gene were
independently amplified by two-step PCR. Primers used for the
amplification of the p16 gene fragment were as follows:
5¢-CGGAGAGGGGGAGAGCAG-3¢ and 5¢-TCCCCTTTTTC-
CGGAGAATTCG-3¢ for exon 1 (Marchetti et al, 1997);
5¢-TCTGAGCTTTGGAAGTTCG-3¢ and 5¢GGAAATTGAAA-
CTGGAAGC-3¢ for exon 2 (Kamb et al, 1994), and
5¢-AGGAATTCGGTAGGGACGGCAAGAGAGG-3¢ and 5¢-
GAAG-CTTGGGGGAAGGCATATATCTACG-3¢ for exon 3
(Marchetti et al, 1997). Primers used for the amplification of the
p15 gene were 5¢-TGGCTCTGACCACTCTGC-3¢ for the sense
primer, which corresponds to nucleotides 61–78, and
5¢-AGCGAATTCGGGTGGGAAATTGGGTAAGAA-3¢ for the
antisense primer, which corresponds to nucleotides 397–426.
Sequences for the primers were described previously by Washimi
et al (1995). The PCR reaction mixture contained 0.1 mg of
genomic DNA, 0.1 mM of each primer, PCR buffer and 5%
dimethyl sulphoxide (DMSO). One cycle of PCR for p16
consisted of 45 s at 94°C (denaturing), 45 s at 50°C for exons 1
and 3 and 45°C for exon 2 (annealing), and 30 s at 72°C (elonga-
tion). One cycle of PCR for p15 consisted of 45 s at 94°C, 30 s at
52°C and 30 s at 72°C. A total of 30 cycles of amplification were
performed. Aliquots (10 ml) of the PCR product were assessed by
2% agarose gel electrophoresis to confirm amplification of the
target. The second step of PCR was performed using 1 ml of the
first step product with 0.05 ml [a-32P]-dCTP (370 MBq ml–1),
0.05 mM of each primer for each gene, independently, 25 mM of
each deoxynucleotide triphosphate, and 0.1 U of Taq polymerase
in a 4 ml total volume, for 10 cycles.
PCR product (2 ml) of exon 2 of p16 or p15 was digested with
10 U of Sma I (Toyobo, Japan) at 30°C in 10 ml of the digestion
buffer recommended by the manufacturer. The PCR product of
p16 was alternatively digested with Hae II and EcoN I (10 U each)
at 37°C. Digestion of the 509-bp fragment of p16 with Sma I
yielded two fragments (260-bp and 249-bp), digestion with Hae II
and EcoN I yielded three fragments (171-bp, 182-bp and 156-bp).
Digestion of the 366-bp fragment of p15 with Sma I yielded two
fragments (149-bp and 217-bp). After incubation for 12 h, diges-
tion was terminated by incubating the mixture at 95°C for 10 min.
Then two volumes of a gel loading buffer (95% formamide, 20 mM
EDTA, 0.05% bromphenol blue and 0.05% xylene cyanol) were
added. The DNA was heat-denatured at 98°C for 10 min. Two
microliters of this mixture was immediately loaded on an 8%
non-denaturing polyacrylamide gel and electrophoresed at a
constant 600 V at 25°C. The gel was vacuum dried and exposed to
Kodak X-Omat film at room temperature for 24 h.
Analysis of p16 gene mutations by sequencing
We purified the PCR-amplified p16 gene fragments on a 2%
agarose gel and subcloned them into the Sma I site of pUC19. A
mixture containing at least 10 subclones selected by colony PCR
was used as the template for DNA sequencing. Sequencing was
performed by the dideoxy termination method using a Sequenase
2.0 kit (USB, Cleveland, OH, USA).
Statistical analysis
The significance of differences in the frequency with which
gene alterations occurred in different categories of lesions was
estimated using the c2 test.
Table 1 Alterations of p16 in uterine tumours
Loss of expression
Histology Mutation/Deletion Hypermethylation mRNA Immunohistochemistry
Cervical tumours 8/40 (20%) 1/32 (3%) 5/19 (26%) 9/33 (27%)
Squamous cell carcinoma 8/35 (23%) 1/27 (4%) 4/16 (25%) 6/28 (21%)
Adenocarcinoma 0/5 (0%) 0/5 (0%) 1/3 (33%) 3/5 (60%)
Endometrial tumours 3/38 (8%) 0/26 (0%) 4/25 (16%) 7/37 (19%)
Complex hyperplasia with atypia 0/8 (0%) 0/6 (0%) 0/3 (0%) 1/7 (14%)
Endometrioid adenocarcinoma 3/30 (10%) 0/20 (0%) 4/22 (18%) 6/30 (20%)
Figure 1 RT-PCR analysis demonstrates the loss of expression of p16
mRNA. RT-PCR generated a 355-bp fragment of the p16 gene (A) and a
319-bp fragment of the b-actin gene (B). PCR products were fractionated in
2.5% agarose gels and visualized by staining with ethidium bromide. Note
that the 319-bp fragment of b-actin was successfully generated in all the
samples analysed (B), whereas fragments of p16 were not amplified in lanes
2, 6, 12, 14 and 15, suggesting the loss of p16 mRNA expression in these
tumours. Lane 1, normal endometrium; lanes 2–7, endometrial carcinoma;
lane 8, normal cervix; lanes 9–16, cervical carcinoma
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Loss of p16 mRNA expression
Expression of p16 mRNA was examined in a total of 44 uterine
tumours by RT-PCR analysis, and compared to that of histologi-
cally normal cervical epithelium and endometrium from four uteri.
A 355-bp fragment of the p16 gene was generated (Figure 1A).The
319-bp fragment of b-actin was amplified independently as a
control (Figure 1B). We successfully amplified both fragments in
all the histologically normal tissues, suggesting that p16 mRNA is
expressed to some extent in the normal uterine cervix and
endometrium. The 319-bp fragment of the b-actin gene was
successfully generated in all 19 cervical tumours and 25 endome-
trial tumours. On the other hand, the only slightly larger 355-bp
fragment of the p16 gene was amplified minimally, or not at all,
in five of 19 (26%) cervical tumours and four of 25 (16%)
endometrial tumours. By cervical tumour sub-type, four of 16
(25%) squamous cell carcinomas and one of three (33%) adeno-
carcinomas had little or no p16 mRNA. For endometrial tumours,
four of 22 (18%) endometrioid adenocarcinomas lacked p16
mRNA (Table 1). The three complex hyperplasia with atypia
tumours each had p16 mRNA. This cumulative data suggests that
p16 mRNA expression was greatly reduced or absent in a small
but significant fraction of human uterine tumours.
Immunohistochemical detection of the p16 gene
product
The p16 protein was examined immunohistochemically in 33
uterine cervical tumours and 37 endometrial tumours (Figure 2).
While normal cervical epithelium and endometrium from four
uteri showed positive p16 staining, both in the nucleus and cyto-
plasm, nine cervical tumours (27%) and seven endometrial
tumours (19%) showed no staining or only weak staining, with the
exception of positively staining lymphoid cells (Table 1). This
included six of 28 (21%) squamous cell carcinomas and three of
five (60%) adenocarcinomas of the uterine cervix, and six of 30
(20%) endometrioid adenocarcinomas and one of seven (14%)
complex hyperplasia with atypia of the uterine corpus. The inten-
sity of the p16 immunohistochemical staining correlated signifi-
cantly with the level of p16 mRNA expression (P < 0.005 by the
c2 test).
Methylation status of the 5¢-CpG island of p16
Methylation of the 5¢-CpG island of the p16 gene was analysed by
multiplex PCR amplification. PCR amplification from undigested
normal tissue DNA yielded a 340-bp fragment of exon 1 of the p16
gene together with the 200-bp fragment of an internal control
(1063.7) fragment. DNA samples were then digested with the
methylation-sensitive restriction endonuclease Sma I and were
then PCR amplified. The 340-bp fragment of the exon 1 of the p16
gene could not be amplified if the Sma I site was unmethylated. In
contrast, the presence of the 340-bp fragment indicated that the
Sma I site was methylated (Figure 3). Of 58 uterine tumours
analysed, only one of 32 (3%) cervical tumours, and none of the 26
endometrial tumours, showed apparent hypermethylation of this
CpG island site. Digestion with the methylation-sensitive restric-
tion enzyme Eag I also suggested the presence of hypermethyla-
tion in only one cervical tumour, one in which hypermethylation
at the Sma I site was also previously demonstrated (data not
shown).
Homozygous deletion of the p16 gene
Deletion of the p16 gene was examined by differential PCR
analysis of a total of 40 cervical tumours and 38 endometrial
tumours. PCR amplification was performed to simultaneously
generate a 111-bp fragment of the exon 2–intron 2 region of the
p16 gene and a 136-bp fragment of the promoter region of the
transferrin receptor gene. The larger transferrin receptor gene frag-
ment, which served as an internal PCR control, was successfully
amplified in all 78 cases, whereas the intensity of the p16 gene
PCR product in five uterine tumours was remarkably reduced
compared to the transferrin receptor gene PCR product (data not
shown). Four were squamous cell carcinomas of the uterine cervix,
and one was an endometrioid adenocarcinoma of the uterine
corpus. We therefore presume that these five cases contained a
homozygous deletion of the p16 gene. The residual signal was
presumably from wild-type stromal and infiltrative cells.
Mutations in the p16 gene
We screened a total of 78 uterine epithelial tumours for p16 muta-
tions by PCR-SSCP (single-strand conformation polymorphism)
analysis. Bands with mobility shifts indicating the presence of
mutation were not observed in either exon 1 or exon 3 of the p16
gene in any of 78 uterine epithelial tumours. However, aberrant
bands were observed in exon 2 of the p16 gene in six of 78 uterine
tumours; four of 40 (10%) cervical tumours and two of 38 (5%)
endometrial tumours. Figure 4 shows an example of multi-
plex–SSCP analysis after Sma I digestion. In these six cases, we
observed one or two bands with mobility shifts that were clearly
distinguishable from the normal alleles, whereas we saw only the
normal allele bands in the remaining 72 cases. Samples which
showed aberrant bands after Sma I digestion also showed bands
after Hae II and EcoN I digestion, whereas none of the remaining
72 tumours did.
Direct sequencing further defined the mutations in the p16 gene.
Sequencing of two or more independently PCR-amplified and
purified DNAs was performed by the dideoxy method (Figure 5).
Single-base substitutions were observed in all six cases. In squa-
mous cell carcinomas of the uterine cervix, mutations identified
were: a mis-sense CTG®ATG mutation (Val®Met) in codon 74;
a mis-sense ACC®ATC mutation (Thr®Ile) in codon 129; and
two silent mutations (GCG®GCA in codon 94 and GGT®GGC
in codon 142) resulting in no amino acid change. In endometrioid
adenocarcinomas of the uterine corpus, a non-sense CGA®TGA
mutation (Arg®stop) in codon 50, and a mis-sense GGG®GAG
mutation (Gly®Glu) in codon 127 were detected. Only the non-
sense stop codon at codon 50 has been previously described in
the database, occurring in a melanoma (Foulkes et al, 1997;
Pollock et al, 1996).
Mutations and homozygous deletions of the p15 gene
We screened a total of 78 uterine epithelial tumours for mutations
in exon 2 of the p15 gene. We PCR amplified a 366-bp fragment
which contained the entire exon 2 of the p15 gene and obtained a
product from most of the tumours. However, three squamous cell
p16 and p15 genes in uterine tumours 461
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carcinomas of the uterine cervix and one endometrioid adenocarci-
nomas of the uterine corpus, which we found to also have a
homozygous deletion of the p16 gene, repetitively failed to yield
this p15 PCR fragment. This suggested that in these tumours the
homologous deletion of the p15 gene extended through the neigh-
bouring  p16 gene. We digested the PCR fragment of the p15
gene with Sma I and subsequently analysed for the presence of
mutations by SSCP analysis. Aberrant bands indicative of point
mutations were not observed in any of the 40 cervical tumours or
38 endometrial tumours.
DISCUSSION
In the present study, we have explored the involvement of the p16
and p15 genes in various types of human uterine tumours. None of
78 tumours had a p15 point mutation. Four tumours shared dele-
tion of the adjoining p15 and p16 genes. We show that p16 inacti-
vation by homologous deletion or point mutation occurs relatively
more frequently in squamous cell carcinomas in the uterine cervix
(23%) than in the adenocarcinomas of the uterine endocervix or
corpus (0% and 10% respectively). We observed mutations only in
exon 2 of the p16 gene, which is in accordance with findings in
other types of human primary tumours, where exon 1 had only 30
mutations compared to 105 reported in exon 2, as reviewed by
Foulkes et al (1997).
Our findings should be considered in light of previous reports
regarding p16 and/or p15 in human uterine tumours (Hatta et al,
1995; Kelly et al, 1995; Peiffer et al, 1995; Hirama et al, 1996;
Wong et al, 1997; Kim et al, 1998; Munirajan et al, 1998). Hatta
et al (1995) found no mutations, deletions, or rearrangements in 15
endometrial carcinomas. Kelly et al (1995) found no homozygous
p16 deletions or point mutations, and no loss of abundant p16
protein expression in 11 cervical cancer cell lines. Peiffer et al
(1995) found 9p21 loss of heterozygosity (LOH) in three of 34
endometrioid tumours, and two tumours which had point muta-
tions, only one of which was accompanied by LOH. Hirama et al
(1996) found no deletion or mutation of p16 in 41 primary cervical
tumours or eight cell lines. Wong et al (1997) found homologous
deletions of p16 in seven of 128 (5%) cervical carcinomas (histo-
logical type not specified) and in one of 41 (2%) endometrial
carcinomas, and they found homozygous deletions of p15 in 19
of 128 (15%) of cervical carcinomas, and in one of 41 (2%)
endometrial carcinomas. Wong et al, found no somatic p16 point
mutations in any of the 128 cervical or 41 endometrial carcinomas.
Kim et al (1998) found no mutations or homozygous deletions of
p15 or p16 in 57 cervical carcinomas. Munirajan et al (1998)
found no p16 mutations in 43 cervical carcinomas.
The incidence of mutations or deletions of p16 in uterine tissues
in various manuscripts may differ due to several factors. When one
analyses primary tumours, contamination with normal stromal
cells or inflammatory cells can cause an underestimation of gene
deletions or mutations. The methods used to evaluate the muta-
tions may also have different sensitivities. Sheffield et al (1993)
   
Figure 2 An immunohistochemical analysis of the p16 gene product finds that normal squamous epithelium of the uterine cervix (A) and normal endocervical
glands (B) show positive staining, whereas the adjacent normal mesenchymal tissue shows negative staining. A squamous cell carcinoma of the uterine cervix
shows positive staining (C). Endocervical adenocarcinomas with positive staining (D) and negative staining (E). Endometrioid adenocarcinomas of the uterine
corpus with positive staining (F and G) and negative staining (H). Scale bars, 0.1 mm in (A), (C), (D) and (E), and 0.05 mm in (B), (F), (G) and (H)
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Figure 3 Analysis of the methylation status of the p16 gene by multiplex
PCR. The 340-bp fragment of exon 1 of the p16 gene and the STS marker
1063.7 were co-amplified. The Sma I-digested (lanes 1, 3, 5, 7 and 9) and
undigested DNA (lanes 2, 4, 6, 8 and 10), derived from cervical carcinomas,
endometrial carcinomas and normal endometrium, were used as templates.
Lanes 1–2, squamous cell carcinoma of the uterine cervix; lanes 3–4, an
endocervical adenocarcinoma; lanes 5–6, a grade-1 endometrioid
adenocarcinoma of uterine corpus; lanes 7–8, a grade-3 endometrioid
adenocarcinoma of the uterine corpus; lanes 9–10, normal endometrium.
Pretreatment with Sma I blocked the amplification of the p16 gene fragment
from an endocervical adenocarcinoma (lane 3), and in two endometrioid
adenocarcinomas (lanes 5 and 7) and a normal endometrium (lane 9),
suggesting that the Sma I site is unmethylated in these tumours and in
normal endometrium. In contrast, the p16 gene fragment was amplified
regardless of the pretreatment with Sma I in a squamous cell carcinoma of
the uterine cervix (lane 1), suggesting that p16 is at least partially methylated
and therefore protected from digestion464 R Nakashima et al
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have suggested that the most important parameter for determining
the sensitivity of SSCP analysis was the size of the fragment. They
found that the optimally sized fragment for sensitive base substitu-
tion detection was approximately 150 bp, at which 95% of muta-
tions were detected. The sensitivity decreases with increases in the
size of the fragment. We have cleaved the 509-bp fragment of exon
2 into two fragments by Sma I digestion, and into three fragments
(171 bp, 182 bp and 156 bp) by Hae II and EcoN I digestion,
before SSCP analysis in order to achieve the best sensitivity and to
have overlapping looks for mutations. Most of the previous studies
used larger and/or non-overlapping fragments for their SSCP
analysis, with presumably less sensitivity. The reason for the
higher incidence of mutations or deletions of p16 in this manu-
script compared to the previous reports may thus be attributed to
the smaller size and/or more rigorous analysis of our fragments.
Most of these previous reports did not fully explore the expres-
sion levels of the p16 mRNA and/or protein in uterine tumours.
We show that two conventional mechanisms of p16 gene
inactivation which occur frequently in other tumour types, i.e.
homozygous deletion or point mutation, occur only rarely in
11 2 11 10 9 8 7 6 5 4 3 2
B
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Figure 4 Detection of p16 gene mutations in cervical carcinoma (A) and in endometrial carcinoma (B) by multiplex–SSCP analysis is shown. The 509-bp
fragment surrounding exon 2 of the p16 gene was PCR amplified, with incorporation of [a-32P]-dCTP. The PCR product was digested with Sma I, heat-
denatured and electrophoresed in an 8% non-denaturing polyacrylamide gel at 25°C. The digested PCR products from wild-type p16 sequences yielded four
bands (arrowheads). In lanes 2 and 5 in (A) and in lanes 2, 6 and 12 in (B), one or two bands with mobility shifts (arrows) are observed, suggesting the
presence of a mutation
Table 2 Uterine tumours with loss of p16 expression
Histology IHCa mRNA Mutation/Deletion Hypermethylation
Cervical tumours
SCC LCNK – – DEL NA
SCC LCNK – – DEL NA
SCC LCNK – – DEL NA
SCC LCNK – NT DEL NA
SCC K – + WT –
SCC K – – WT +
AC G1 – – WT –
AC G1 – + WT –
AC G3 ± +W T–
Endometrial tumours
AC G1 – – DEL NA
AC G1 – – NON-SENSE –
AC G2 – – WT –
AC G3 – NT WT –
AC G2 – – WT NT
AC G1 ± +W T–
CH-A – + WT –
aIHC, immunohistochemistry; SCC, squamous cell carcinoma; AC, adenocarcinoma; CH-A, complex hyperplasia with atypia; LCNK, large-cell non-keratinizing
type; K, keratinizing type; G, histological grade; NT, not tested; DEL, deletion; WT, wild-type; NA, not analysed because p16 is deleted.p16 and p15 genes in uterine tumours 465
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adenocarcinomas of the uterine endocervix or endometrium.
However, we do find that expression of the mRNA and/or protein
from the intact p16 gene is frequently decreased or undetectable in
many of these tumours. We have observed an absence of p16
mRNA expression in 33% of the endocervical adenocarcinomas
and 18% of the endometrial adenocarcinomas.
We found that aberrant expression of the p16 protein is observed
in 60% of endocervical adenocarcinomas and 20% of endometrial
adenocarcinomas. Using the same antibody for immunohisto-
chemistry, Shiozawa et al (1997) and Lu et al (1998) report that
normal endometrial and cervical cells stain negatively for p16
protein, except for during the proliferative phase, and then only
cytoplasmically. Shiozawa et al found 14/41 endometrioid types
endometrial tumours were positive for p16, and Lu et al found
23/40 cervical carcinomas were positive for p16. We cannot
explain the discrepancy between our positive staining of normal
uterine tissues and the negative staining of these two groups.
Recent studies show that aberrant hypermethylation of the CpG
islands associated with the p16 and the p15 genes might provide
an alternative mechanism for gene inactivation, versus the muta-
tion or deletion of these genes. It has been established that the
methylation status of the 5¢ promoter/enhancer region CpG islands
is associated with the level of gene transcription. In normal cells
expressing these genes the CpG islands are usually hypomethy-
lated. Acquired hypermethylation has been associated with loss of
their mRNA expression (Gonzalez-Zulueta et al, 1995; Herman
et al, 1995, 1996; Merlo et al, 1995). Strikingly, aberrant methyla-
tion of the p16 gene was observed frequently not only in
neoplasms such as breast and renal cell carcinomas, where
homozygous deletion is frequent, but also in the tumours, such as
colon and prostate carcinomas, in which homozygous deletions of
the p16 gene are rare (Herman et al, 1995).
The mechanism of aberrant expression of the p16 gene product
in these uterine tumours was evaluated (Table 2). Of nine cervical
carcinomas and seven endometrial tumours with aberrant p16 gene
product, four cervical carcinomas and one endometrial carcinoma
had homozygous deletion of p16, and one endometrial carcinoma
had a non-sense mutation in p16. Of the remaining five cervical
tumours and five endometrial tumours having no deletion or
mutation in p16 gene, two cervical tumours and two endometrial
tumours did not express p16 mRNA. Of these four uterine tumours
with loss of p16 mRNA expression, one squamous cell carcinoma
showed hypermethylation within the 5¢-CpG island of the p16
gene. However, the remaining three tumours had no discernable
mechanisms to explain their loss of p16 mRNA expression.
Although the specific CpG sites we examined are a frequent target
for hypermethylation in human cancers, methylation of other sites
might be involved in these remaining three tumours. A mechanism
of specific transcription factor repression or deficiency is also
possible. It is notable that aberrant expression of p16 protein was
observed in five tumours which otherwise showed positive mRNA
expression. There may yet exist an alternative translational
mechanism, or post-translational degradative mechanism, for the
loss of protein expression in these unique tumours.
The association of aberrant p16 expression with clinical stages
was evaluated. In cervical carcinomas, the aberrant p16 expression
was found in none of one (0%) stage 0 tumours, three of 12 (25%)
stage 1 tumours, three of 16 (19%) stage 2 tumours, two of three
(67%) stage 3 tumours and one of one (100%) stage 4 tumours. In
endometrial carcinomas, the aberrant p16 expression was found
in three of 14 (21%) stage 1 tumours, one of eight (13%) stage 2
tumours, two of seven (29%) stage 3 tumours, and none of one
(0%) stage 4 tumours. Therefore, there was no association
between aberrant p16 expression and clinical stages.
The process of tumorigenesis usually involves the activation of
oncogenic and inactivation of tumour suppressor signaling path-
ways. Activation of the K-ras oncogene, frequently mutated in
human carcinomas, drives tumour growth forward. Inactivation of
some part of the p53 and Rb tumour suppressor pathways is
usually required to permit the uncontrolled growth. It is well estab-
lished that human papillomavirus (HPV) infection is strongly
associated with cervical carcinogenesis. The E6 and E7 proteins of
the oncogenic strains of HPV bind and inactivate both the p53 and
RB proteins respectively. HPV infection can thus often substitute
for mutations in both these pathways. For example, Parker et al
(1997) found that HPV and p53 overexpression were mutually
exclusive in cervical carcinomas, whereas Munirajan et al (1998)
found that, of 43 tumours studied with p53 mutations, three of four
tumours had HPV infections.
All 33 cervical carcinomas in which we examined the p16
expression by immunohistochemistry had been analysed previ-
ously for the presence of HPV infection (Fujita et al, 1992).
Therefore, the association of p16 immunoreactivity with HPV
infection was evaluated. The aberrant p16 expression was found in
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five of 25 (20%) HPV-positive tumours and four of eight (50%)
HPV-negative tumours (P = 0.117 by Fisher’s exact test). The
finding that p16 inactivation was more frequent in HPV-negative
tumours than in HPV-positive tumours (50% vs 20%) follows the
predictions based on the molecular biology discussed above. Kim
et al (1998) found none of 57 cervical carcinomas had p16 or p15
point mutations or homozygous loss of the 9p21 locus.
On the other hand, we previously showed that activation of the
K-ras oncogene and inactivation of the p53 tumour suppressor
gene occurs in about 31% and 25% of endometrial carcinoma
respectively (Enomoto et al, 1993). We examined the p16 expres-
sion by immunohistochemistry in 27 of 30 endometrial carcinomas
we had analysed previously for the presence of K-ras activation
and p53 inactivation (Enomoto et al, 1993). The association of
p16 immunoreactivity with K-ras activation was evaluated. The
aberrant p16 expression was found in two of seven (29%) tumours
with K-ras activation and in four of 20 (20%) tumours with
wild-type K-ras sequence (P = 0.50 by Fisher’s exact test). The
association of p16 immunoreactivity with p53 inactivation was
evaluated. The aberrant p16 expression was found in two of five
(40%) tumours with p53 inactivation and in four of 22 (18%)
tumours with wild-type p53 sequence (P = 0.303). These observa-
tions suggest that p16 inactivation occurs independently to the
K-ras activation or p53 inactivation.
The p15 and p16 genes possess extensive sequence similarity and
both are co-localized on chromosome 9p21. The p15 protein also
binds to and inhibits CDK function in vitro, and ectopic expression
of p15 inhibits cell growth in vitro (Stone et al, 1995). In spite of the
sequence similarity between the p15 and p16 genes and their
proteins, however, the two proteins have significantly different func-
tions in vivo. The p15 gene is induced by transforming growth factor
(TGF-b), but the p16 gene is not (Hannon and Beach, 1994). The
expression of p15 is independent of RB regulation, unlike the p16
gene. Not only the physiological functions, but also their role as
tumour suppressor genes, seem to differ between the two genes.
Point mutations in p16 are found in tumours with varying frequency,
depending on the tumour type, but are extremely rare in the p15
gene (Stone et al, 1995). Inactivation of the p16 gene by hyperme-
thylation occurs in many human solid tumours. However, inactiva-
tion of p15 by CpG-island hypermethylation occurs selectively in
leukaemias and gliomas, but not in colon, breast or lung carcinomas
(Herman et al, 1995). These previous reports suggest that the p15
gene is not an important target for inactivation in most human
cancers. Our observations, that a p15 mutation did not occur in any
of the 78 uterine tumours, and that homozygous deletion of the p15
gene was observed in only four cases, all of which also had homozy-
gous deletion of p16, suggest that the p15 gene is not the primary
target for deletion in this locus, and p15 may not play an important
role in uterine tumorigenesis.
In conclusion, the p16 gene is a tumour suppressor gene which
is inactivated in a significant number of uterine tumours, although
its exact role in uterine tumorigenesis remains to be established.
Although the homologous co-deletion of the p15 gene may occur
in a small fraction of uterine cervical and endometrial tumours
(4/78), this gene appears not to play an important role in uterine
carcinogenesis.
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